4.36

2.83% 0.12

After Hours: 4.37 0.010 +0.23%

Verastem Inc (VSTM)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Verastem Inc stock is traded at $4.36, with a volume of 1.74M. It is up +2.83% in the last 24 hours and down -26.23% over the past month. Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Previous Close:

$4.24

Open:

$4.37

24h Volume:

1.74M

Relative Volume:

0.84

Market Cap:

$383.13M

Revenue:

$30.91M

Net Income/Loss:

$-209.47M

P/E Ratio:

-1.3101

EPS:

-3.3279

Net Cash Flow:

$-147.13M

1W Performance:

+5.06%

1M Performance:

-26.23%

6M Performance:

-58.98%

1Y Performance:

-47.53%

1-Day Range:

$4.265

$4.50

1-Week Range:

$4.00

$4.50

52-Week Range:

$4.00

$11.24

Verastem Inc Stock (VSTM) Company Profile

Name

Verastem Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(781) 292-4200

Address

117 KENDRICK STREET, NEEDHAM, MA

Employee

102

Twitter

@VerastemOncolog

Next Earnings Date

2026-05-07

Latest SEC Filings

VSTM's Discussions on Twitter

Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VSTM Verastem Inc	4.36	372.58M	30.91M	-209.47M	-147.13M	-3.3279
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	BTIG Research	Buy
Feb-04-26	Initiated	H.C. Wainwright	Buy
Oct-16-25	Resumed	Cantor Fitzgerald	Overweight
Apr-10-25	Initiated	Jefferies	Buy
Mar-24-25	Reiterated	H.C. Wainwright	Buy
Dec-31-24	Reiterated	BTIG Research	Buy
Sep-30-24	Initiated	Guggenheim	Buy
Nov-21-23	Resumed	BTIG Research	Buy
Sep-27-23	Initiated	B. Riley Securities	Buy
Jun-15-23	Upgrade	Mizuho	Neutral → Buy
Sep-07-22	Resumed	Alliance Global Partners	Buy
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight
Apr-14-22	Initiated	RBC Capital Mkts	Outperform
Mar-09-22	Initiated	Truist	Buy
Jul-01-21	Initiated	Alliance Global Partners	Buy
May-24-21	Upgrade	BTIG Research	Neutral → Buy
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy
May-02-18	Initiated	Seaport Global Securities	Buy
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy
Sep-07-17	Reiterated	H.C. Wainwright	Buy
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy
Sep-29-15	Downgrade	Cantor Fitzgerald	Buy → Hold
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-29-15	Downgrade	Jefferies	Buy → Hold
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-28-15	Downgrade	Mizuho	Buy → Neutral
Sep-28-15	Downgrade	ROTH Capital	Buy → Neutral
Sep-09-15	Initiated	Raymond James	Strong Buy
May-12-15	Reiterated	UBS	Buy
Apr-08-15	Initiated	H.C. Wainwright	Buy
Jan-23-15	Reiterated	ROTH Capital	Buy
Jul-08-14	Resumed	Oppenheimer	Perform
Feb-11-14	Initiated	Mizuho	Buy

View All

Verastem Inc Stock (VSTM) Latest News

06:22 AM

Director Brian Stuglik (VSTM) awarded 36,000 Verastem RSUs with 2026–2027 vesting - Stock Titan

06:22 AM

06:21 AM

Verastem (NASDAQ: VSTM) awards 36,000 RSUs to director Rowinsky - Stock Titan

06:21 AM

06:19 AM

Verastem (VSTM) director Michelle Robertson awarded 36,000 RSUs - Stock Titan

06:19 AM

06:18 AM

Verastem (VSTM) director Anil Kapur receives 36,000 RSU equity award - Stock Titan

06:18 AM

06:12 AM

Verastem (VSTM) director awarded 36,000 RSUs vesting through 2027 - Stock Titan

06:12 AM

Verastem (VSTM) director gets 36,000 RSU award vesting through 2027 - Stock Titan

06:12 AM

11:57 AM

Verastem Oncology Appoints Michael P. Bailey to Board of Directo - GuruFocus

11:57 AM

08:15 AM

Verastem (VSTM) stockholders back board slate, equity plans and auditor at 2026 meeting - Stock Titan

08:15 AM

07:49 AM

Verastem Oncology appoints Michael Bailey to board - Investing.com

07:49 AM

07:30 AM

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors - Yahoo Finance

07:30 AM

May 22, 2026

Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

May 20, 2026

May 18, 2026

Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView

May 18, 2026

Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

May 18, 2026

May 17, 2026

Verastem Q3 2025 Earnings Preview - MSN

May 17, 2026

May 15, 2026

Foresite (VSTM) holds 3,146,631 shares, reporting 3.6% stake - Stock Titan

May 15, 2026

Armistice Capital 5.23% stake in Verastem (VSTM) via managed fund - Stock Titan

May 15, 2026

RTW Funds, Roderick Wong Report 9.99% of Verastem (VSTM) - Stock Titan

May 15, 2026

Balyasny-affiliated holders report 1.36M shares in Verastem (VSTM) - Stock Titan

May 15, 2026

Verastem Oncology announces management changes - MSN

May 15, 2026

May 14, 2026

VSTM Maintained by Mizuho -- Price Target Lowered to $14.00 - GuruFocus

May 14, 2026

MSN Money - MSN

May 14, 2026

Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - Moomoo

May 14, 2026

May 13, 2026

Verastem, Inc. drives patient-focused efforts in rare ovarian cancer awareness - Traders Union

May 13, 2026

Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14 - Moomoo

May 13, 2026

May 12, 2026

Press Release: Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Moomoo

May 12, 2026

Verastem Oncology to Present at Upcoming Investor Conferences - Barchart.com

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 11, 2026

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results - simplywall.st

May 11, 2026

Verastem, Inc. (NASDAQ:VSTM) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance

May 11, 2026

May 10, 2026

VSTM Slides As Verastem Inc. Selling Pressure Builds - timothysykes.com

May 10, 2026

May 09, 2026

BTIG Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $18 - Moomoo

May 09, 2026

Verastem Q1 Earnings Call Highlights - Barchart

May 09, 2026

Verastem (VSTM) Q4 Revenue Reaches US$17.5 Million Yet Heavy Losses Reinforce Bearish Views - Sahm

May 09, 2026

Verastem, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VSTM) 2026-05-09 - Seeking Alpha

May 09, 2026

May 08, 2026

RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15 - Moomoo

May 08, 2026

Verastem Inc Earnings Call Highlights Growth And Risk - TipRanks

May 08, 2026

Verastem (VSTM) Q1 2026 Earnings Transcript - AOL.com

May 08, 2026

VSTM Maintained by BTIG -- Price Target Lowered to $18.00 - GuruFocus

May 08, 2026

(VSTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily

May 08, 2026

Q1 2026 Verastem Inc Earnings Call Transcript - GuruFocus

May 08, 2026

Verastem stock price target lowered to $18 by BTIG on revenue miss - Investing.com Canada

May 08, 2026

New rare ovarian cancer guide aims to ease diagnosis-to-care hurdles - Stock Titan

May 08, 2026

MA-VERASTEM-ONCOLOGY - Black Hills Pioneer

May 08, 2026

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer - ChartMill

May 08, 2026

Verastem Q1 2026 Earnings Call Transcript - MarketBeat

May 08, 2026

Verastem: Q1 Earnings Snapshot - theheraldreview.com

May 08, 2026